Skip to content
Home/Companies/Biotech/Scorpion Therapeutics
Scorpion Therapeutics

Scorpion Therapeutics

Biotech·US·Exited 2025·Held 5yr
Entry
2020
Hold
5yr
Exit
2025

Who owns Scorpion Therapeutics?

Scorpion Therapeutics was owned by Abingworth through Abingworth Bioventures VII (2018 vintage) from 2020 to 2025, exited via Trade Sale.

Buyer identity available on Pro.

Hand-verified · updated 2026-06-10

Abingworth
Investor
Abingworth
Abingworth Bioventures VII · 2018 · Life Sciences VC

Key facts

HQUS
SectorBiotech
StatusActive
Websiteinvestor.lilly.com
Exit Type
Trade Sale
Buyer
MOIC
–
Exit Year
2025

More from Abingworth Bioventures VII

Other portfolio companies in the same fund.

Adicet Bio
Adicet Bio
Active
BiotechUS· 2021
Soteria Biotherapeutics
Soteria Biotherapeutics
Active
HealthcareUS· 2021
Atsena Therapeutics
Atsena Therapeutics
Active
BiotechUS· 2020
Orbus Therapeutics
Orbus Therapeutics
Active
HealthcareUS· 2020
Q32 Bio
Exited 2024
BiotechUS· 2020
Spruce Biosciences
Spruce Biosciences
Exited 2020
BiotechUS· 2020

More PE-backed in Biotech

Comparable biotech deals from other GPs.

Antiverse
Antiverse
Active
Future Planet CapitalUK
CellCentric
CellCentric
Active
Future Planet CapitalUK
Crescendo Biologics
Crescendo Biologics
Active
Future Planet CapitalUK
Cytox Group
Exited 2024
Future Planet CapitalUK
GenSight Biologics
GenSight Biologics
Active
Sofinnova PartnersFrance
Healx
Healx
Active
Amadeus Capital PartnersUK
Track Scorpion Therapeutics

Save this record to your watchlist and pick up your research where you left off. No spam.

Create free account

Get the full record on Scorpion Therapeutics.

Free. No credit card. 30 seconds. Exit buyers and MOIC on Pro.

Hand-checked deal notes on this investment
Save this company to your watchlist
Exit buyer and MOIC on this deal (Pro)
or
Continue with email

Already a member? Sign in

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue